Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Medical Technologies has completed the development of the Prostate Cancer FISH Detection Kit, a molecular diagnostic test based on the Fluorescent in situ Hybridization technology.
Subscribe to our email newsletter
The company expects to launch the Kit in July 2008. The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues.
Xiaodong Wu, chairman and CEO of China Medical Technologies, said: “The successful development of the Kit is a milestone in expanding our Fluorescent in situ Hybridization (FISH)reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007.”